Razuprotafib for COVID-19: real-time analysis of 2 studies

Download Image

Post

c19early.org

Razuprotafib for COVID-19

2 studies with 134 patients

Serious outcome risk

Razuprotafib

Control

COVID-19 Razuprotafib studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (2)−10%

Mortality (2)−10%

RCTs (2)−10%

RCT mortality (2)−10%

Late (2)−10%

00.511.5+

← Razuprotafib
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

Razuprotafib (AKB-9778) is a small molecule inhibitor of vascular endothelial protein tyrosine phosphatase (VE-PTP) administered via subcutaneous injection. By inhibiting VE-PTP, the drug restores Tie2 receptor signaling, which promotes vascular stability and reduces endothelial permeability.


	Covid Analysis	Meta-analysis of razuprotafib studies
	Meta-analysis of razuprotafib studies
Mar 3 2023	Files et al., eClinicalMedicine, doi:10.1016/j.eclinm.2023.101889	Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial
	10% higher mortality (p=0.81). RCT severe COVID-19 patients showing no significant difference in outcomes with razuprotafib.
Feb 26 2021	Paggiarino et al., NCT04511650	Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Escalation and Proof-of-Concept Study to Evaluate the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019
	178% higher progression (p=0.37) and 469% lower hospital discharge (p=0.28). RCT 29 patients showing no significant differences with razuprotafib treatment.